Axogen (AXGN) Cash & Equivalents (2010 - 2026)

Axogen has reported Cash & Equivalents for 17 years, with the latest figure at $82.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 356.75% year-over-year to $82.7 million; the trailing twelve-month figure through Mar 2026 stood at $82.7 million (up 356.75% YoY), and the FY2025 full-year result was $35.5 million, up 29.01% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $82.7 million, up from $35.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $82.7 million in Q1 2026, with the low at $7.7 million in Q1 2023.
• Average Cash & Equivalents over 5 years is $24.1 million, with a median of $19.2 million recorded in 2024.
• Year-over-year, Cash & Equivalents tumbled 77.73% in 2022 and surged 356.75% in 2026.
• Tracing AXGN's Cash & Equivalents over 5 years: stood at $15.3 million in 2022, then soared by 102.98% to $31.0 million in 2023, then slipped by 11.18% to $27.6 million in 2024, then climbed by 29.01% to $35.5 million in 2025, then surged by 132.51% to $82.7 million in 2026.
• The last three Cash & Equivalents figures came in at $82.7 million (Q1 2026), $35.5 million (Q4 2025), and $23.9 million (Q3 2025), per Business Quant data.

Peer Comparison